- Home
- DHC vs CRVS Comparison
DHC vs CRVS Comparison
Compare DHC & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHC
- CRVS
- Stock Information
- Founded
- DHC 1998
- CRVS 2014
- Country
- DHC United States
- CRVS United States
- Employees
- DHC N/A
- CRVS N/A
- Industry
- DHC Real Estate Investment Trusts
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- DHC Real Estate
- CRVS Health Care
- Exchange
- DHC Nasdaq
- CRVS Nasdaq
- Market Cap
- DHC 629.7M
- CRVS 516.0M
- IPO Year
- DHC N/A
- CRVS 2016
- Fundamental
- Price
- DHC $2.44
- CRVS $7.39
- Analyst Decision
- DHC Hold
- CRVS Buy
- Analyst Count
- DHC 3
- CRVS 4
- Target Price
- DHC $4.50
- CRVS $12.83
- AVG Volume (30 Days)
- DHC 856.3K
- CRVS 765.4K
- Earning Date
- DHC 11-04-2024
- CRVS 11-12-2024
- Dividend Yield
- DHC 1.66%
- CRVS N/A
- EPS Growth
- DHC N/A
- CRVS N/A
- EPS
- DHC N/A
- CRVS N/A
- Revenue
- DHC $1,477,343,000.00
- CRVS N/A
- Revenue This Year
- DHC N/A
- CRVS N/A
- Revenue Next Year
- DHC $5.26
- CRVS N/A
- P/E Ratio
- DHC N/A
- CRVS N/A
- Revenue Growth
- DHC 6.62
- CRVS N/A
- 52 Week Low
- DHC $2.19
- CRVS $1.30
- 52 Week High
- DHC $4.24
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- DHC 34.07
- CRVS 40.84
- Support Level
- DHC $2.33
- CRVS $7.88
- Resistance Level
- DHC $2.50
- CRVS $8.33
- Average True Range (ATR)
- DHC 0.11
- CRVS 0.56
- MACD
- DHC 0.02
- CRVS -0.19
- Stochastic Oscillator
- DHC 26.83
- CRVS 30.55
About DHC Diversified Healthcare Trust of Beneficial Interest
Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. It operates through two segments: Office Portfolio and SHOP. The office portfolio includes medical office properties leased to medical-related businesses and life sciences properties. The SHOP segment runs communities that offer multiple types of residential care, ranging from independent living to nursing services. DHT operates across the United States and the majority of its revenue derives from rents and medical programs.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).